BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hanna-Sawires RG, Schiphuis JH, Wuhrer M, Vasen HFA, van Leerdam ME, Bonsing BA, Mesker WE, van der Burgt YEM, Tollenaar RAEM. Clinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer. Int J Mol Sci 2021;22:2655. [PMID: 33800786 DOI: 10.3390/ijms22052655] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Tabang DN, Ford M, Li L. Recent Advances in Mass Spectrometry-Based Glycomic and Glycoproteomic Studies of Pancreatic Diseases. Front Chem 2021;9:707387. [PMID: 34368082 DOI: 10.3389/fchem.2021.707387] [Reference Citation Analysis]
2 Rivera D. Emerging Role for 7T MRI and Metabolic Imaging for Pancreatic and Liver Cancer. Metabolites 2022;12:409. [DOI: 10.3390/metabo12050409] [Reference Citation Analysis]
3 Lageveen-Kammeijer GSM, Kuster B, Reusch D, Wuhrer M. High sensitivity glycomics in biomedicine. Mass Spectrom Rev 2021;:e21730. [PMID: 34494287 DOI: 10.1002/mas.21730] [Reference Citation Analysis]
4 Khakoo S, Petrillo A, Salati M, Muhith A, Evangelista J, Seghezzi S, Petrelli F, Tomasello G, Ghidini M. Neoadjuvant Treatment for Pancreatic Adenocarcinoma: A False Promise or an Opportunity to Improve Outcome? Cancers (Basel) 2021;13:4396. [PMID: 34503206 DOI: 10.3390/cancers13174396] [Reference Citation Analysis]
5 Vellan CJ, Jayapalan JJ, Yoong BK, Abdul-Aziz A, Mat-Junit S, Subramanian P. Application of Proteomics in Pancreatic Ductal Adenocarcinoma Biomarker Investigations: A Review. Int J Mol Sci 2022;23:2093. [PMID: 35216204 DOI: 10.3390/ijms23042093] [Reference Citation Analysis]
6 Xu Y, Wang Y, Höti N, Clark DJ, Chen SY, Zhang H. The next "sweet" spot for pancreatic ductal adenocarcinoma: Glycoprotein for early detection. Mass Spectrom Rev 2021;:e21748. [PMID: 34766650 DOI: 10.1002/mas.21748] [Reference Citation Analysis]